In brief
Sperm DNA fragmentation means damage involving breaks in sperm DNA. Specialised tests assess this in a semen sample; routine semen analysis measures other features. A fragmentation result is not a diagnosis of every fertility difficulty, a genetic carrier screen or an individual prediction of pregnancy.
Current UK NICE guidance, published 31 March 2026, advises against sperm DNA integrity testing in the fertility pathway. This deserves a clear place in any discussion of the test. A different measurement is not automatically a useful additional investigation, and finding a high value does not establish a treatment that improves live birth.
This guide explains the terminology, the report and the decisions that can follow. You may want knowledge without a test, support with unresolved conception, or help navigating treatment. Men have reproductive questions of their own; the same relevant anatomy can also apply to trans women and non-binary people. No relationship status or immediate pregnancy plan is required to learn.
Key takeaways
- Routine semen analysis and DNA-fragmentation testing answer different laboratory questions.
- NICE NG257 advises against sperm DNA integrity testing; it is not a routine upgrade after a normal semen report.
- Methods and their decision values are not interchangeable. There is no universal DFI percentage that predicts your outcome.
- Recurrent pregnancy loss needs a specialist pathway; an association with DNA damage cannot assign the cause of an individual loss.
- An improved laboratory value and an improved chance of a live birth are different outcomes.
- Agree what would change, the evidence, cost, risks and review plan before considering any additional investigation or intervention.
What is sperm DNA fragmentation?
DNA carries genetic information. In sperm it is tightly packaged, but damage can involve breaks in one or both strands. Fragmentation tests examine aspects of DNA integrity in a collected sample. They do not read every gene or establish whether an inherited condition could be passed on.
Think of sperm assessment as several separate questions. How many sperm are present? How do they move? What do their shapes look like? What does a particular DNA assay measure? Those questions are related to reproduction, but their answers cannot be collapsed into one “sperm quality” mark.
A result describes the material tested under the laboratory’s conditions. It is not a judgement of masculinity, health behaviour, identity or someone’s ability to be a parent. The practical question is whether knowing it would support a better decision.
How is it different from semen analysis?
Routine semen analysis assesses features including sperm concentration, movement and shape. It is a foundation of male reproductive assessment when testing is appropriate. DNA-fragmentation testing is separate; neither a normal count nor a morphology value directly supplies a DNA-fragmentation result.
A reassuring semen report should remain reassuring about its measured features. It does not certify every stage of reproduction, but that limitation is not a reason to assume hidden DNA damage. A specialist considers symptoms, history, the conception route and what has already been assessed before proposing further investigations.
In the Fertility Dance, sperm production and delivery sit alongside ovulation, eggs, transport, fertilisation, the uterus and pregnancy maintenance. Unresolved conception can require a joined-up assessment of the relevant stages and people. A single additional sperm number cannot investigate that whole sequence.
What does current UK guidance say?
NICE NG257 recommendation 1.17.6 advises against testing sperm DNA integrity (fragmentation). The guideline was published on 31 March 2026. Its rationale identifies uncertainty about the relationship with subfertility, the testing and definitions, and effective treatment. This is broader than saying that everybody should test after a normal semen analysis.
Some clinics nevertheless discuss the test. Ask which specific clinical question they are addressing and how the proposal fits current UK guidance. The explanation should cover proceeding without the test as well as proceeding with it. Availability in a private clinic is not evidence of clinical benefit.
Guidance helps frame an informed conversation; it is not a requirement to postpone learning, advice, a semen analysis or appropriate clinical assessment until a set duration of trying. A time-sensitive preservation or treatment question needs its own timely pathway.
SCSA, TUNEL, SCD and Comet: why the method matters
Names you may encounter include sperm chromatin structure assay (SCSA), TUNEL, sperm chromatin dispersion (SCD, sometimes called a halo test) and Comet. Ask for the exact assay and what its reported measure represents. A shared percentage sign does not make two laboratory methods equivalent.
A prospective observational study published in 2015 compared SCSA and TUNEL in men assessed for subfertility at a tertiary andrology clinic. The methods frequently disagreed on normal/abnormal classification. This finding concerns comparability in a selected clinic population; it is not a general-population risk estimate, pregnancy prediction or proof that a particular person’s report is wrong.
The study supports a practical rule: do not move a threshold from one method to another. Nor should one laboratory’s result be treated as an improvement or deterioration from another laboratory without checking comparability.
| Report term | What to establish | What not to assume |
|---|---|---|
| SCSA / DFI | Which assay, reporting scale and laboratory decision value were used? | That its percentage is equivalent to TUNEL. |
| TUNEL | How does this laboratory measure and report labelled DNA damage? | That an SCSA boundary can interpret it. |
| SCD / halo | What does the laboratory’s dispersion classification mean? | That a familiar kit name supplies an outcome forecast. |
| Comet | Which endpoint and reporting system appear on the report? | That every Comet result uses the same scale as DFI. |
What does a high DFI percentage mean?
DFI stands for DNA fragmentation index, a term used on some reports. The laboratory should explain its calculation and the meaning of its reference or decision value. “High” is a classification within that system, not a statement that the same percentage of pregnancies will miscarry or the same percentage of future children will have a condition.
Keep the method, date, laboratory comments, preparation and sample details beside the number. For example, a percentage copied into a message without the assay name cannot safely be interpreted using an online chart. Ask what the provider can conclude from the report and how confident that conclusion is.
A result also cannot identify which individual sperm will fertilise an egg or determine the full developmental potential of an embryo. Do not turn “below the threshold” into guaranteed fertility, or “above the threshold” into a declaration that natural conception or treatment cannot work.
Does the result identify a cause?
A measurement of DNA damage does not, by itself, name its cause. It cannot distinguish all possible contributions from health, medicines, the reproductive tract or exposures. Nor does it prove that DNA damage caused an individual failed cycle or pregnancy loss.
A purposeful clinical history can include previous testicular problems, surgery, infections, recent illness, prescribed and non-prescribed medicines, testosterone or anabolic-steroid use, smoking and occupational exposures. A clinician decides which details need examination or investigation. Mention them directly rather than trying to diagnose yourself from a fragmentation category.
Do not stop medicines to change a laboratory number. Discuss any suspected effect with the prescriber and, where appropriate, a fertility-medicine or urology specialist. The aim is appropriate care for the person, not simply a more reassuring colour on a report.
Collection, preparation and comparing samples
If testing is being considered after an informed clinical discussion, obtain the laboratory’s exact instructions before collection. Clarify the abstinence interval, container, collection method, transport conditions and delivery timing. Do not assume instructions for one service apply to another.
Tell the provider about incomplete collection, delay, recent illness or other departures from the instructions. Ask whether the sample is suitable and whether those circumstances limit interpretation. Do not conceal a collection problem to avoid an inconvenient repeat.
Before repeating, agree the purpose: resolving a sampling issue, checking reproducibility or evaluating a decision are different reasons. Ask whether the same laboratory and method are needed, what interval is meaningful and what change would alter care. Repeating until a preferred value appears is not a plan.
DNA fragmentation and recurrent pregnancy loss
Recurrent loss merits its own specialist assessment and emotional support. It should not become an investigation directed solely at the person carrying the pregnancy, or a search for somebody to blame.
ESHRE’s recurrent-pregnancy-loss guideline, updated in 2022 and issued in January 2023, conditionally allows consideration of sperm DNA fragmentation for diagnostic purposes in that specific population. It also recognises uncertainty about the most informative and reliable test. This differs from NICE’s 2026 fertility-pathway recommendation and is not an instruction for routine screening.
Ask the recurrent-loss team to explain the scope of the guideline they are using, the evidence relevant to your history and whether a result would change management. An association observed across groups does not establish why a particular pregnancy ended. A high result must not be used to assign responsibility for a loss.
Does high fragmentation mean you need ICSI or testicular sperm?
No automatic treatment choice follows from the label alone. IVF, ICSI, sperm-selection methods and surgical sperm retrieval are different interventions with different indications and burdens. A clinic should explain the proposed route in the context of the full treatment history.
The HFEA’s September 2026 review assesses interventions offered after fragmentation testing, rather than rating the tests themselves. It reports insufficient good-quality evidence for the rated interventions to establish an improvement in the chance of having a baby. Testicular retrieval also introduces procedural risks; a semen-sample test and an invasive retrieval are not equivalent decisions.
Ask for the outcome that matters: live birth, not only a lower laboratory value, a different selected sample or an embryo-development measure. Also ask whether evidence comes from people with circumstances like yours. The decision and any changes to an active treatment protocol remain with the treating team.
Can supplements improve DNA fragmentation or fertility outcomes?
A plausible antioxidant mechanism is not enough to establish clinical benefit. In the US MOXI randomised trial, published in 2020, an antioxidant combination did not significantly improve DNA-fragmentation changes versus placebo after three months. The study was limited in size; it does not establish that every supplement or every clinical situation is identical.
The larger Dutch SUMMER randomised trial, published in 2025, included 1,171 men seeking fertility care in its analysis. The tested supplement did not significantly improve its primary ongoing-pregnancy outcome versus placebo. Participants received standard care; it was not a trial restricted to people with high DNA fragmentation. Its findings should not be relabelled as a high-DFI treatment success rate.
Neither study supports a blanket promise that a supplement will repair sperm DNA or improve the chance of a baby. Discuss nutritional needs, medicines and any existing supplements with an appropriate professional rather than stacking high-dose products. Treatment for a diagnosed deficiency is a separate clinical question.
What useful action can you take without chasing a number?
NHS sperm-health advice includes stopping smoking, avoiding anabolic steroids and recreational drugs, moderating alcohol and reducing relevant workplace chemical exposures. These are useful health conversations without first needing a DNA-fragmentation purchase. They cannot guarantee a particular laboratory change or pregnancy.
Make actions specific to your circumstances. A smoking-cessation referral, medication conversation or occupational-health assessment has a clearer purpose than an unspecified promise to “detox sperm”. Where a possible physical problem is identified, clinical examination determines whether treatment is appropriate; an online category cannot do that.
Agree a review date and what will be reviewed: symptoms, adherence to an agreed action, a clinically indicated measurement or the treatment plan. Necessary specialist care must not be postponed while waiting for lifestyle changes or a target number.
Future fertility, preservation and occupational exposure
If you are learning before parenthood is on the agenda, you do not need to prove a fertility problem to ask questions. Equally, DNA-fragmentation testing cannot certify future fertility, show that an exposure was harmless or provide a personal expiry date for sperm.
For potentially fertility-affecting treatment, hormone changes, surgery or cancer care, ask promptly about preservation before treatment starts where feasible. The immediate decision may concern collection, storage and the treating team’s timetable. Do not delay that pathway to complete an optional add-on or an optimisation programme.
Occupational questions should name the actual exposure, duration and protective arrangements. Bring the relevant workplace information to occupational health. A generic semen panel or reassuring fragmentation result cannot assess every chemical, heat or deployment risk.
Solo, donor and LGBTQ+ family-building routes
Focus on the role in reproduction. A sperm provider, egg provider and person carrying a pregnancy may be different people. Two men considering surrogacy have independent reproductive histories; one person’s result cannot stand in for the other’s.
For donor conception, ask the regulated service what screening and sample-quality assessment apply to the route. Fragmentation testing is not a replacement for infection screening, genetic assessment when relevant, consent or legal advice. Do not infer that a donor with an unmeasured DFI is unsafe.
Tell the team about anatomy, hormones, surgery and the language you prefer. Ask about privacy, accessible collection arrangements and who can receive your results. Practical access and dignity belong in the assessment, rather than being treated as optional extras.
A practical decision map before an additional test
Write down the actual decision before discussing the package. “Would this change the timing or type of treatment?” is more useful than “Could it tell me anything else?” Information can be interesting without improving care, particularly if both possible results lead to the same action.
Ask for the complete cost and what is included: collection, laboratory work, interpretation, any repeat and proposed interventions. No price is quoted here because services and inclusions differ. Consider the emotional and time costs as well as the bill.
If no useful decision follows, continuing with an appropriate existing pathway can be an active choice. If a specialist proposes an exception, ask them to document the rationale, uncertainty and review point. You can ask questions without either accepting every add-on or dismissing your concern.
| Your starting point | Useful conversation | Avoid assuming |
|---|---|---|
| Learning or planning ahead | Which reproductive-health question do I want answered? | Everyone needs a baseline DFI. |
| First assessment or normal semen analysis | What does current guidance support, and what would change? | Normal semen automatically requires advanced testing. |
| Recurrent loss | Which specialist pathway and guideline apply to this history? | One high result identifies the cause of the losses. |
| IVF/ICSI preparation | What outcome evidence supports the proposed intervention? | Lower DFI guarantees better treatment outcomes. |
| Time-sensitive preservation | What needs to happen before the planned medical treatment? | Optional testing should delay essential care. |
Questions to ask your clinician or laboratory
What is the precise clinical question? Why this test despite the current NICE recommendation? Which method and laboratory will be used? What does its decision value mean? What would you recommend if the result were high, and if it were not?
Is the proposed action already sensible without testing? What evidence shows the action improves live birth in a comparable population? What are the harms, uncertainties, full costs and alternatives? Would declining the add-on change access to core treatment?
Who explains the result, what would warrant a repeat, and when will the plan be reviewed? If you are already in treatment, establish who has responsibility for changes so advice does not conflict across services.
How ProFertility fits your next step
ProFertility connects education, purposeful testing and clinical care. The relevant addition is an explanation of the reproductive question and a proportionate route forward, not an assumption that everyone needs a more advanced test. Learning through the Library or free Frank membership can be enough for now.
A focused fertility-medicine or urology consultation may suit a specific concern, symptoms, preservation planning or a proposed intervention. Where agreed work on modifiable factors needs follow-through, the six-month ProFertility Plan connects assessment, relevant targeted investigations, clinical review, tailored action and reviews.
A programme does not guarantee lower fragmentation, pregnancy or avoiding IVF. It can sit alongside necessary treatment, with the treating clinicians retaining responsibility for medicines and treatment decisions. Choose support for the task you actually want help with.
Related guidance and support
Related blog articles
Frequently asked questions
What is sperm DNA fragmentation?
It is damage involving breaks in sperm DNA. Specialised assays assess aspects of this in a semen sample; they do not measure every reproductive function or read every gene.
Is DNA fragmentation included in routine semen analysis?
No. Semen analysis assesses features including concentration, movement and shape. Fragmentation testing is separate and is not an automatic next step after a normal result.
Does NICE recommend sperm DNA fragmentation testing?
NICE NG257, published 31 March 2026, advises against sperm DNA integrity testing in the fertility pathway. Ask how any proposed test fits that current recommendation.
What is a normal DFI?
There is no universal percentage for every method and clinical setting. Ask the reporting laboratory to explain its assay, decision value and limitations.
Does 30% DNA fragmentation mean a 30% miscarriage risk?
No. A laboratory percentage is not an individual miscarriage probability. It cannot establish the cause of a pregnancy loss.
Can I compare SCSA and TUNEL results?
Do not treat them as interchangeable. They assess different aspects of DNA integrity; method-specific results and decision values need their own interpretation.
Does high fragmentation mean I need ICSI or surgical sperm retrieval?
No automatic treatment choice follows. Ask the treating team about indication, evidence for live birth, risks and alternatives in your circumstances.
Do antioxidants repair sperm DNA?
A benefit cannot be promised. Randomised trials of particular supplements have not established routine fertility benefit; formulations and populations differ.
Should recurrent pregnancy loss prompt this test?
Discuss the question with the recurrent-loss team. ESHRE conditionally allows consideration in this specific population, while current NICE fertility guidance advises against testing. The team should explain the evidence and management consequences.
Can a low result guarantee future fertility?
No. It cannot certify future fertility, the safety of an exposure or a treatment outcome. Preservation and clinical planning depend on the relevant history and goals.
Clinical sources
- NICE NG257, recommendation 1.17.6: Fertility problems—assessment and treatment; published 31 March 2026.
- NICE NG257: rationale and impact, sperm DNA fragmentation; 2026.
- HFEA: Sperm DNA fragmentation; published 24 September 2026. The review rates interventions following testing, not the assays themselves.
- ASRM ReproductiveFacts: Sperm DNA integrity testing—what is it? Revised 2023.
- Stahl and colleagues: Concordance among sperm DNA integrity assays and semen parameters. Fertility and Sterility, 2015;104:56–61.e1. Original study abstract hosted by Weill Cornell.
- ESHRE: Recurrent Pregnancy Loss Guideline, update 2022; final version January 2023, male factors pages 91–94.
- Steiner and colleagues: MOXI randomised clinical trial. Fertility and Sterility, March 2020;113:552–560.e3.
- de Ligny and colleagues: SUMMER randomised clinical trial. JAMA Network Open, September 2025;8:e2532405.
- NHS: Low sperm count; last reviewed 26 January 2024, current page accessed 15 October 2026.
Source check: 2026-10-15. This guide is educational and does not replace individual medical advice.